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Introduction 
This document represents an update of the last version of the Swiss Association for the Study of the 
Liver (SASL) and Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement (EOS) 
on the Treatment of Chronic Hepatitis C published in November 2017 (www.sasl.ch; 
www.sggssg.ch, www.sginf.ch). Recommendations are based on the results of phase 3 or 
selected phase 2 clinical studies (1-10), the European Association for the Study of the Liver 
(EASL) Recommendations on Treatment of Hepatitis C (www.easl.eu) (11) and the 
Recommendations by the American Association for the Study of Liver Diseases (AASLD) and the 
Infectious Diseases Society of America (IDSA) (http://hcvguidelines.org). The reader is referred to 
these documents as well as the 'Fachinformation' approved by Swissmedic 
(www.compendium.ch or www.swissmedicinfo.ch) and the "Spezialitätenliste" of the Swiss Federal 
Office of Public Health (FOPH) (www.spezialitaetenliste.ch) for further information, including key 
references and sustained virologic response (SVR) rates that can be expected with the different 
treatment regimens as well as current reimbursement. The Swiss HCV Advisor App 
(www.hcvadvisor.com) is based on this EOS and has been endorsed by SASL and SSI. It 
provides rapid information on recommended treatment regimens. 
The landscape of hepatitis C treatment has changed dramatically over the last years. At this point, it is 
unlikely that additional drugs for the treatment of hepatitis C will be licensed in the future. An 
exhaustive discussion of all aspects is beyond the scope of this EOS. Its aim is rather to provide 
practical and concise guidance. 
Sofosbuvir alone (Sovaldi®), daclatasvir (Daklinza®), simeprevir (Olysio®), the ledipasvir/sofosbuvir 
fixed-dose combination (Harvoni®) as well as the combination of ritonavir-boosted paritaprevir, 
ombitasvir and dasabuvir (Viekirax® and Exviera®) are no longer included in this update, as they have 
been largely replaced by newer direct acting antivirals (DAAs). Please consult the SASL-SSI EOS of 
November 2017 (available from the secretaries of SASL and SSI) for information on these drugs and 
drug combinations. 
Treatment should be evaluated and can now be offered to all persons with HCV infection. However, 
reimbursement of DAAs is still limited to prescription by gastroenterologists, infectious diseases 
specialists and selected, named other specialists (www.bag.admin.ch/ls-ref). 
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Background 
Hepatitis C virus (HCV) chronically infects 60-80 million individuals worldwide (12). A recent report 
commissioned by the FOPH estimates that 36,000-43,000 persons are chronically infected in 
Switzerland (13). 
Recommendations for healthcare provider-initiated testing for HCV infection have been issued by the 
Swiss Experts in Viral Hepatitis (SEVHep) and the FOPH (14). Complementary screening modalities 
are being considered within the framework of the Swiss Hepatitis Strategy (www.hepatitis-schweiz.ch) 
(15). 
The clinical course of chronic hepatitis C depends on a number of modifiable (alcohol, coinfections 
with hepatitis B virus [HBV] or human immunodeficiency virus [HIV], non-alcoholic fatty liver disease) 
and unmodifiable factors (age at the time of infection, sex, genotype 3, host genetics); 2-20% may 
develop cirrhosis over the first 20 years of infection, and disease progression may be accelerated in a 
non-linear fashion thereafter, with an estimated 15-30% developing cirrhosis after 30 years. Current 
efforts and goals set by the WHO and the Swiss Hepatitis Strategy aim to reduce the disease burden 
(decompensated liver cirrhosis hepatocellular carcinoma [HCC], liver transplantation [LT] and 
mortality), which in Switzerland has been projected to reach a peak only around 2030 if more efficient 
means of screening and treatment were not implemented (16, 17). 
 
Pre-treatment assessment 
Before starting antiviral treatment, other causes that contribute to the progression of liver disease 
should be carefully evaluated. All patients should be tested for markers of HBV (HBsAg, anti-HBc, 
anti-HBs) and HIV coinfection. Patients without previous hepatitis A virus or HBV exposure or 
vaccination should be vaccinated. 
Hepatitis B reactivation has been observed in HBsAg-and/or anti-HBc-positive patients during or after 
antiviral treatment for HCV (18). Therefore, concurrent antiviral treatment with an HBV nucleos(t)ide 
analogue is recommended in HBsAg-positive patients. In patients with negative HBsAg but positive 
anti-HBc ± anti-HBs EASL recommends to monitor ALT and to test for HBsAg and HBV DNA in those 
in which ALT does not normalize or rises during or after antiviral therapy of chronic hepatitis C (11). 
Alcohol consumption should be determined and quantified. Specific counseling to stop any harmful 
alcohol use should be provided. In addition, components of the metabolic syndrome (weight, BMI, 
diabetes mellitus, hyperlipidemia, arterial hypertension) should be determined and appropriate 
counseling and/or treatment initiated, as indicated. Other causes of chronic liver disease such as 
hemochromatosis should also be excluded. 
As current treatment regimens are partially determined by the fibrosis stage and previous treatments, 
a detailed treatment history has to be obtained. The stage of fibrosis can be assessed with either a 
liver biopsy or transient elastography (FibroScan®). In patients with cirrhosis, determination of liver 
function (Child-Pugh score) and assessment of portal hypertension are essential. Protease inhibitor-
based treatment regimens should only be considered in patients with well-compensated liver function 
(Child-Pugh A) and without history of prior decompensation. 
Before deciding on the treatment regimen and treatment duration, it is important to determine the HCV 
genotype and serum HCV RNA load. If the viral genotype has not been determined recently, HCV 
genotyping should be repeated. 
In order to gather real-life data on the natural history and outcomes of HCV infection in Switzerland, 
we encourage the inclusion of HCV-infected patients in the Swiss Hepatitis C Cohort Study (SCCS; 
www.swisshcv.org) or of HIV-coinfected patients in the Swiss HIV Cohort Study (SHCS; 
www.shcs.ch). 
 
Practical use of the grazoprevir/elbasvir fixed-dose combination 
Grazoprevir (GZR), a second-generation HCV NS3-4A protease inhibitor, and elbasvir (EBR), an 
NS5A inhibitor, are available in a fixed-dose combination of 100 mg GZR and 50 mg EBR (Zepatier®, 
Merck, Kenilworth, NJ). It is administered at a dose of one tablet per day with or without food. 
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GRZ/EBR shows activity against HCV genotypes 1 as well as 4 and is approved and reimbursed in 
Switzerland for the treatment of these two genotypes. It is listed only for patients with HCV genotype 
1b infection in the updated recommended treatment options (Table 1) but may still be considered also 
for treatment-naïve patients with HCV genotype 4 infection and a baseline HCV RNA < 8 x 105 IU/ml. 
GZR/EBR is generally well tolerated; the most commonly reported adverse effects are fatigue and 
headache. Liver enzymes should be measured before treatment initiation and at week 8 during 
treatment because in 1% of the study patients an elevation has been observed. For drug-drug 
interactions and contraindicated co-medications, please consult www.hep-druginteractions.org or 
other sources. 
Dose modification in patients with renal impairment is not necessary. GZR/EBR can therefore be used 
in patients with advanced renal impairment (19). GZR/EBR is contraindicated in case of significant 
liver impairment (Child-Pugh B and C) or in patients with a history of decompensation. 
In patients with HCV genotype 1a baseline resistance testing has to be performed to identify potential 
NS5A polymorphisms (M28T/A, Q30E/H/R/G/K/L/D, L31M/V/F and Y93C/H/N) as these significantly 
reduce rates of SVR12 with a 12-week course of GZR/EBR. If such a polymorphism has been 
detected the total GZR/EBR treatment duration is 16 weeks in combination with weight-based ribavirin 
(RBV; 1000 mg [< 75 kg] to 1200 mg [≥ 75 kg] per day in two doses). Resistance testing is reimbursed 
by the manufacturer of GZR/EBR. Prolongation of GZR/EBR treatment to 16 weeks in combination 
with RBV is also indicated for patients with genotype 4 infection who failed a previous treatment with 
PEG-IFN-α and RBV (relapse excluded). However, the 16-week regimens comprising RBV are no 
longer recommended in light of the currently available alternatives. 
 
Practical use of the velpatasvir/sofosbuvir fixed-dose combination 
Velpatasvir (VEL) is an NS5A inhibitor and sofosbuvir (SOF) a nucleotidic polymerase inhibitor, both 
with pangenotypic activity. They are administered once daily with or without food in a fixed-dose 
combination single pill containing 100 mg of VEL and 400 mg of SOF (Epclusa®, Gilead Sciences, 
Foster City, CA). 
VEL/SOF is generally well tolerated; the most commonly reported adverse effects include headache, 
fatigue and nausea. For drug-drug interactions and contraindicated co-medications, please consult 
www.hep-druginteractions.org or other sources. The combination of SOF and another DAA with 
amiodarone has been linked to instances of severe bradycardia and is therefore contraindicated. Due 
to the long half-life of amiodarone, interaction with SOF is possible for several months after 
discontinuation of amiodarone. Therefore, it is recommended to wait for at least 3 months after 
discontinuation of amiodarone before starting a SOF-containing regimen. If considered necessary, a 
proton pump inhibitor (PPI) at a maximum dose equivalent to 20 mg omeprazole may be taken 4 
hours after VEL/SOF. Similarly, H2 receptor antagonists may be administered simultaneously with or 
12 hours apart from VEL/SOF at a dose that does not exceed doses comparable to famotidine 20 mg 
twice daily. 
SOF and its main metabolite GS-331007 are eliminated predominantly by the kidney. Therefore, 
VEL/SOF is not recommended in patients with severe renal impairment (GFR < 30 ml/min). VEL/SOF 
has been studied in patients with decompensated cirrhosis (5) and was generally well tolerated in this 
setting. Therapeutic drug monitoring for SOF and GS-331007 is available at the Division of Clinical 
Pharmacology of the CHUV (www.chuv.ch/pcl). 
Safety and efficacy of VEL/SOF were assessed in the phase III Astral studies as well as in Polaris 
studies 2 and 3 (3-5, 10). This combination therapy achieved cure rates > 95% across all genotypes. 
Suboptimal SVR rates were only observed in genotype 3-infected cirrhotic or treatment-experienced 
patients with pre-existing NS5A RASs (particularly the Y93H substitution). Accordingly, the presence 
of this variant should be excluded or RBV added in this situation (Table 1). 
 
Practical use of the voxilaprevir/velpatasvir/sofosbuvir fixed-dose combination 
Voxilaprevir (VOX), a second-generation HCV NS3-4A protease inhibitor, is administered once daily 
with food in a fixed-dose combination single pill containing 100 mg of VOX, 100 mg of VEL and 400 
4 
mg of SOF (Vosevi®, Gilead Sciences, Foster City, CA). The combination has pangenotypic activity. It 
is approved by Swissmedic for patients who failed an NS5A inhibitor-containing regimen but it is not 
reimbursed yet. Hence, reimbursement has to be requested under article 71 
(https://www.vertrauensaerzte.ch/tools/dynaforms_kvv71/). 
VOX/VEL/SOF is generally well tolerated. The most commonly reported adverse effects include 
headache, diarrhea and nausea; gastrointestinal side effects are more common than with VEL/SOF 
alone. For drug-drug interactions and contraindicated co-medications, please consult www.hep-
druginteractions.org or other sources. Concomitant treatment with amiodarone is contraindicated (see 
above). If considered necessary, a PPI at a maximum dose equivalent to 20 mg omeprazole may be 
taken 4 hours after VOX/VEL/SOF. 
VOX/VEL/SOF is not recommended in patients with severe renal impairment (GFR < 30 ml/min; see 
above). VOX/VEL/SOF is contraindicated in case of significant liver impairment (Child-Pugh B and C) 
or in patients with a history of decompensation. 
VOX/VEL/SOF is recommended as salvage therapy in patients who do not achieve an SVR after a 
DAA-based regimen other than SOF combined with PEG-IFN-α and RBV or SOF combined with RBV. 
It is given for 12 weeks without RBV in patients with genotype 1-6 infection without or with 
compensated cirrhosis. The adjunction of RBV may be considered in very difficult-to-cure patients 
such as cirrhotic patients with resistance to two DAA classes or in cirrhotic patients with genotype 3 
infection and resistance to NS5A inhibitors (http://hcvguidelines.org) (11). However, this is not 
supported by study data. 
 
Practical use of the glecaprevir/pibrentasvir fixed-dose combination 
Glecaprevir (GLE), a second-generation HCV NS3-4A protease inhibitor, and pibrentasvir (PIB), a 
second-generation NS5A inhibitor, are available in a fixed-dose combination of 100 mg GLE and 40 
mg PIB (Maviret®, AbbVie, North Chicago, IL). The combination has pangenotypic activity. It is 
administered once daily at a dose of three tablets with food. GLE/PIB shows pangenotypic activity. 
GLE/PIB is generally well tolerated; the most commonly reported adverse effects include headache 
and fatigue. For drug-drug interactions and contraindicated co-medications, please consult www.hep-
druginteractions.org or other sources. 
Dose modification in patients with renal impairment is not necessary. GLE/PIB can therefore be used 
in patients with advanced renal impairment (20). GLE/PIB is contraindicated in case of significant liver 
impairment (Child-Pugh B and C) or in patients with a history of decompensation. 
 
HCV RNA monitoring on treatment 
It is recommended to determine HCV RNA at baseline, week 2 or 4 (assessment of adherence, 
optional), week 12 or 24 (end of treatment, optional), at 12 weeks after the end of treatment (SVR12) 
and 3-9 months later (i.e. 6 to 12 months after the end of treatment, optional). 
 
Follow-up after SVR 
If HCV RNA is negative 6 to 12 months after the end of treatment, patients can be considered as 
definitively cured. HCV RNA determination is no longer necessary, unless the patient has an ongoing 
or new risk behavior for HCV reinfection (illicit drug use, high-risk sexual practices). 
Patients with an indication for HCC surveillance as recommended by international guidelines should 
continue to have 6-monthly abdominal ultrasound and - depending on local custom - alpha-fetoprotein 
measurement. EASL recommends HCC surveillance for all patients with Metavir stage ≥ F3 or 
FibroScan > 9.5 kPa, other guidelines (e.g. EACS) recommend HCC surveillance for cirrhotic patients 
only. FibroScan > 12.5 kPa is considered to indicate cirrhosis. Patients with cirrhosis should undergo 
screening for esophageal varices as recommended in the Baveno VI consensus statement (21). 
According to this statement, patients with compensated cirrhosis can safely avoid endoscopy in case 
of a platelet count > 150 G/L and a FibroScan < 20 kPa. Patients without advanced liver disease (F0-
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F2; FibroScan ≤ 9.5 kPa) but with cofactors for liver disease progression (alcohol use, metabolic 
syndrome, non-alcoholic fatty liver disease etc.) should be periodically (once a year) assessed for liver 
disease progression. Patients without significant liver fibrosis (Metavir F0-F1; FibroScan < 7.5 kPa) 
and without risk factors for disease progression can be released from specialized care. 
 
Special patient populations 
Response rates to DAAs are similar in HCV-HIV-coinfected as compared to HCV-monoinfected 
patients. Therefore, treatment indications and regimens for HCV-HIV-coinfected patients should in 
general follow those of HCV-monoinfected patients. Specific recommendations for the management of 
HCV infection in HIV-infected patients are updated regularly by the European AIDS Clinical Society 
(www.eacsociety.org). Because of the frequent co-medication with antiretrovirals and other drugs, it is 
crucial to check for drug-drug interactions (www.hep-druginteractions.org) before starting DAA 
treatments. However, in the large majority of patients, drug-drug interactions are manageable and 
should not be a barrier to starting DAA therapy. 
Ledipasvir/sofosbuvir (LDV/SOF) may still be used in treatment-naïve patients with HCV genotype 1 
infection, Metavir fibrosis stage ≤ F2 and HCV RNA < 6 x 106 (6.8 log) IU/ml who desire an 8-week 
treatment or in rare cases for HIV-coinfected individuals on an etravirine-, efavirenz- or nevirapine-
based antiretroviral regimen with no other option. 
Expert advice should be sought for adolescents as well as patients with DAA failure, decompensated 
cirrhosis, HCC, renal insufficiency, pre- or post-LT, other organ transplant recipients and acute 
hepatitis C. 
Patients with decompensated cirrhosis 
Antiviral treatment of patients with decompensated liver disease (Child-Pugh B and C) should be 
pursued in close collaboration with an experienced center. These patients should be evaluated for LT. 
Protease inhibitor-based regimens are contraindicated in patients with Child-Pugh B and C cirrhosis. 
They can be treated with LDV/SOF (genotype 1) or VEL/SOF (all genotypes) in combination with 
weight-based RBV (1000 mg or 1200 mg per day in patients < 75 or ≥ 75kg, respectively) (5, 22, 23). 
The combination of LDV/SOF with RBV is not foreseen in the Swiss label and not reimbursed. RBV 
can be started at a dose of 600 mg and increased to the recommended dose as tolerated. If RBV is 
contraindicated or not tolerated, treatment should be prolonged to 24 weeks, but this is not foreseen 
for VEL/SOF in the Swiss label and is not reimbursed. As adverse events are more frequent in 
patients with decompensated liver disease, close monitoring is mandatory. In patients on the LT 
waiting list and with a MELD score > 18-20, treatment might be deferred until after LT, depending on 
the estimated waiting time 
Retreatment of patients with DAA failure 
Resistance testing is recommended in patients who do not achieve an SVR after a DAA-based 
regimen other than SOF combined with PEG-IFN-α and RBV or SOF combined with RBV. 
Reimbursement for resistance testing should be clarified beforehand. 
VOX/VEL/SOF for 12 weeks is recommended as salvage therapy in patients who do not achieve an 
SVR after a DAA-based regimen other than SOF combined with PEG-IFN-α and RBV or SOF 
combined with RBV. It is approved by Swissmedic but not reimbursed yet for this indication (see 
above). VOX/VEL/SOF is contraindicated in case of significant liver impairment (Child-Pugh B and C) 
or in patients with a history of decompensation. The adjunction of RBV may be considered in very 
difficult-to-cure patients such as cirrhotic patients with resistance to two DAA classes or in cirrhotic 
patients with genotype 3 infection and resistance to NS5A inhibitors (http://hcvguidelines.org) (11). 
However, this is not supported by study data. 
The combination of GLE/PIB and SOF represents an alternative to VOX/VEL/SOF. However, this 
combination is not approved and the same restrictions apply in patients with decompensated cirrhosis 
(Child-Pugh B and C). 
6 
Recommended treatment options for patients with chronic hepatitis C 
Recommended treatment options are summarized in Table 1. 
 
Table 1. Recommended treatment options for patients with chronic hepatitis C. 
A. Treatment-naïve patients 
Genotype Non-cirrhotic Cirrhotic (Child-Pugh A) 
1a VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
1b GZR/EBR for 12 wks1 
VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
GZR/EBR for 12 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
2 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
3 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF ±  RBV for 12(-24) wks2 
GLE/PIB for 12 wks 
VOX/VEL/SOF for 12 wks 
4 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
5 and 6 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
 
Color code: green = approved and reimbursed (please consult www.spezialitaetenliste.ch for eventual 
updates); blue = according to the current Swiss label, but with potential modifications of treatment 
duration and/or the addition of RBV; bordeaux = off-label use of a drug approved but not reimbursed yet in 
Switzerland. 
1 Treatment-naïve patients with Metavir fibrosis stage ≤ F2 may be treated for 8 weeks. 
2 Patients with cirrhosis should be treated with VEL/SOF + RBV for 12 weeks or with VEL/SOF for 24 
wks if RBV-intolerant. Extension to 24 weeks in patients who cannot tolerate RBV requires 
approval by health insurances. If NS5A resistance testing is performed and demonstrates the 
absence of NS5A RAS Y93H, treatment can be performed with VEL/SOF for 12 weeks without RBV. 
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B. Treatment-experienced patients (defined as patients who were previously treated with PEG-
IFN-α and RBV; SOF, PEG-IFN-α and RBV; or SOF and RBV) 
Genotype Non-cirrhotic Cirrhotic (Child-Pugh A) 
1a VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
1b GZR/EBR for 12 wks 
VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
GZR/EBR for 12 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
2 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
3 VEL/SOF ± RBV for 12(-24) wks3 
GLE/PIB for 16 wks 
VEL/SOF ± RBV for 12(-24) wks4 
GLE/PIB for 16 wks 
VOX/VEL/SOF for 12 wks 
4 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
5 and 6 VEL/SOF for 12 wks 
GLE/PIB for 8 wks 
VEL/SOF for 12 wks 
GLE/PIB for 12 wks 
 
Color code: green = approved and reimbursed (please consult www.spezialitaetenliste.ch for eventual 
updates); blue = according to the current Swiss label, but with potential modifications of treatment 
duration and/or the addition of RBV; bordeaux = off-label use of a drug approved but not reimbursed yet in 
Switzerland. 
3 The use of RBV in treatment experienced patients without cirrhosis is discussed controversially. EASL 
recommends VEL/SOF for 12 weeks while AASLD recommends VEL/SOF for 12 weeks in the 
absence of NS5A RAS Y93H and VEL/SOF + RBV for 12 weeks in the presence of NS5A RAS Y93H. 
VEL/SOF for 24 wks may be considered in the latter case if RBV-intolerant. Extension to 24 weeks in 
patients who cannot tolerate RBV requires approval by health insurances. 
4 Treatment experienced patients with cirrhosis should be treated with VEL/SOF + RBV for 12 weeks or 
with VEL/SOF for 24 wks if RBV-intolerant. Extension to 24 weeks in patients who cannot tolerate 
RBV requires approval by health insurances. If NS5A resistance testing is performed and 
demonstrates the absence of NS5A RAS Y93H, treatment can be performed with VEL/SOF for 12 
weeks without RBV. 
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